Bevacizumab (anti-VEGF antibody) and cetuximab (anti-EGFR antibody) are integral portion of the treatment guidelines for colorectal cancer [37] and prediction of treatment response to these agents is currently based on the tumor’s molecular profile [37–39]. The gene discussed is VEGFA; the disease is neoplasm.